17:I[66739,["/_next/static/chunks/0.3dg.jzl0xwf.js?dpl=dpl_wni71eTQeio7irGWmurLp7HRfDNL","/_next/static/chunks/05hx6kuf6-oy4.js?dpl=dpl_wni71eTQeio7irGWmurLp7HRfDNL","/_next/static/chunks/0~heydqc5smtk.js?dpl=dpl_wni71eTQeio7irGWmurLp7HRfDNL","/_next/static/chunks/0juapqyy99ga..js?dpl=dpl_wni71eTQeio7irGWmurLp7HRfDNL","/_next/static/chunks/12fz8clx4-stp.js?dpl=dpl_wni71eTQeio7irGWmurLp7HRfDNL","/_next/static/chunks/06dn~uer6.43l.js?dpl=dpl_wni71eTQeio7irGWmurLp7HRfDNL"],"default"] 19:I[38632,["/_next/static/chunks/0qqtp3r0h7kah.js?dpl=dpl_wni71eTQeio7irGWmurLp7HRfDNL","/_next/static/chunks/0iukvycbd42rl.js?dpl=dpl_wni71eTQeio7irGWmurLp7HRfDNL"],"IconMark"] 18:T43e,

In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Hilary Rosselot, Executive Director, National Fragile X Foundation

Jordi Fàbrega, Co-Founder & CEO, CONNECTA Therapeutics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Fragile X at a turning point: Breaking through the clinical bottleneck

BioSpace

Fragile X at a turning point: Breaking through the clinical bottleneck